Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Conditions
- Resectable Hepatocellular Carcinoma
Interventions
- DRUG: Atezolizumab and Bevacizumab
Sponsor
Fundacion Clinic per a la Recerca Biomédica